Pharmaceutical News

RSS

Trial of new type of drug that attacks amyloid

Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer’s disease patients.

4 Nov 2004

Pfizer licenses drug from University of Rochester for treatment of hot flashes

The University of Rochester has signed a license agreement with Pfizer which will allow Pfizer to market a specific class of non-hormonal drugs for the treatment of hot flashes associated with menopause.

4 Nov 2004

Cyclooxygenase (COX) inhibitors tested in both prevention and treatment clinical trials

Numerous compounds are examined by the National Cancer Institute (NCI) for their potential to prevent or treat cancer. One class of compounds, cyclooxygenase (COX) inhibitors, is currently being tested in both prevention and treatment clinical trials.

4 Nov 2004

FDA fast tracks investigational anti-cancer drug, phenoxodiol

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, Fast Track status for its intended use in patients with recurrent ovarian cancer.

4 Nov 2004

Psoriasis trial enters final stage

Solbec Pharmaceuticals Ltd today announced the successful completion of the first two stages of the Phase I clinical trial of its lead compound, CoramsineTM (SBP002), for the treatment of psoriasis.

4 Nov 2004

European approval for Taxotere (docetaxel) in prostate cancer

Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.

4 Nov 2004

Cholesterol-lowering drugs can interact with grapefruit juice and increase the risk of the drugs' potential side-effects

Britain's Medicines and Healthcare Products Regulatory Agency recently issued prescribing advice reminding healthcare professionals that certain cholesterol-lowering drugs, namely Zocor (simvastatin) and Lipitor (atorvastatin), can interact with grapefruit juice and increase the risk of the drugs' potential side-effects.

4 Nov 2004

FDA warns against use of Actra-Rx and Yilishen

The U.S. Food and Drug Administration has warned consumers not to purchase or to consume Actra-Rx or Yilishen, two products promoted and offered for sale on Web sites as "dietary supplements" for treating erectile dysfunction and enhancing sexual performance for men.

4 Nov 2004

Guidance for generic drugs

The U.S. Food and Drug Administration (FDA) has announced that a Guidance for Industry entitled "Listed Drugs, 30-Month Stays, and Approval of ANDAs and 505(b)(2) Applications Under Hatch-Waxman, as Amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003

4 Nov 2004

Wyeth shows new Phase III data about its investigational antibiotic, tigecycline

Wyeth Pharmaceuticals recently presented exciting new Phase III data about its investigational antibiotic, tigecycline, based on a clinical trial in patients with complicated intra-abdominal infections (cIAI).

4 Nov 2004

Analysis shows Remicade reduces pain associated with Crohn's disease

According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.

2 Nov 2004

Maxim Pharmaceuticals to withdraw NDA for advanced malignant melanoma

Maxim Pharmaceuticals has announced that based upon the negative outcome of it's confirmatory Phase 3 clinical trial (M0104) studying Ceplene(TM) (histamine dihydrochloride) in combination with Interleukin-2 (IL-2) in advanced malignant melanoma patients with liver metastases, it plans to close the treatment protocol approved by the FDA earlier this year.

2 Nov 2004

New vaccines to counter biological agents such as anthrax

Scientists at Imperial College London and Hammersmith Hospital are to help develop new vaccines in case of a terrorist release of biological agents such as anthrax.

1 Nov 2004

Studies show Pfizer's Azithromycin Microspheres effective as treatment for respiratory tract infections

Pfizer Inc.'s new investigational microsphere formulation of azithromycin, which is dosed as a one-time-only oral antibiotic, is comparable to other frequently prescribed treatments for some of the most common respiratory tract infections in adult patients.

1 Nov 2004

Tentative approval of testosterone gel product

Par Pharmaceutical Companies today announced that its partner, Paddock Laboratories, has been granted tentative approval by the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for testosterone gel 1%.

1 Nov 2004

No evidence that Glatiramer acetate slows multiple sclerosis progression

In this week's issue of the Lancet Neurology, glatiramer acetate, known as Copaxone(R), was subjected to an independent review. The systematic review, called a Cochrane Review, performed by Dr. Luca Munari and colleagues, challenges the claims of benefit from previous industry- based publications.

1 Nov 2004